Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661469 | 1.00 | LGALS8 (0.33) | LGALS8LGALS3 | |
| SCHEMBL12292292 | 1.00 | LGALS8 (0.33) | LGALS8LGALS3 | |
| SCHEMBL23660466 | 0.87 | CA1 (0.33) | — | |
| SCHEMBL21481959 | 0.87 | — | — | |
| SCHEMBL21123603 | 0.85 | — | — | |
| SCHEMBL14624334 | 0.85 | — | — | |
| SCHEMBL14537230 | 0.85 | — | — | |
| SCHEMBL22317546 | 0.85 | — | — | |
| SCHEMBL26253255 | 0.85 | — | — | |
| SCHEMBL14295972 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210338830-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210187003-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210169919-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | SAREPTA THERAPEUTICS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200291427-A1 | CRISPR-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE | GEMINI THERAPEUTICS INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200190516-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | SAREPTA THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-02-06 | — | — | US | disclosed |
| US-20190316121-A1 | Modified Guide RNAs | INTELLIA THERAPEUTICS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-06-13 | — | — | US | disclosed |
| US-20190015440-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-01-17 | — | — | US | disclosed |
| US-20180216111-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190516-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | MTPN, SMN1; SMN2, UTRN | LGALS8 3271/4885LGALS3 3888/4885 |
| US-20200040020-A1 | PROCESSES FOR PREPARING OLIGOMERS | NOP2, PCBP1, RNGTT | LGALS8 1972/4885LGALS3 3240/4885 |
| US-20190015440-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | LGALS8 2845/4885LGALS3 4260/4885 |
| US-11802283-B2 | Oligonucleotide analogues targeting human LMNA | LMNB2, LMNA, LMNB1 | LGALS8 260/4885LGALS3 623/4885 |
| US-11642364-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, DCLRE1B | LGALS8 2714/4885LGALS3 3735/4885 |
| US-20210338830-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | LGALS8 2367/4885LGALS3 3604/4885 |
| US-20190177723-A1 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS | UTRN, SMN1; SMN2, MTPN | LGALS8 1135/4885LGALS3 1558/4885 |
| US-20210169919-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | LGALS8 2714/4885LGALS3 3735/4885 |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | PCBP1, RNGTT, PHAX | LGALS8 2578/4885LGALS3 3703/4885 |
| US-11491238-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | LGALS8 2868/4885LGALS3 3980/4885 |
| US-20230381216-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | LGALS8 2714/4885LGALS3 3735/4885 |
| US-20200291427-A1 | CRISPR-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE | HTRA1, HTRA2, MTREX | LGALS8 576/4885LGALS3 500/4885 |
| US-20180177814-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, DCLRE1B | LGALS8 2714/4885LGALS3 3735/4885 |
| US-20210187003-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | RBM17, UTRN, UPF1 | LGALS8 2941/4885LGALS3 3870/4885 |
| US-20190262375-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | RBM17, UTRN, UPF1 | LGALS8 2941/4885LGALS3 3870/4885 |
| US-20210145852-A1 | Combination Therapies for Treating Muscular Dystrophy | UTRN, MBNL1, TNNC1 | LGALS8 1101/4885LGALS3 1992/4885 |
| US-11384105-B2 | Processes for preparing oligomers | NOP2, RNGTT, PCBP1 | LGALS8 1827/4885LGALS3 3071/4885 |
| US-20200377886-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | UTRN, SMN1; SMN2, RBM17 | LGALS8 2367/4885LGALS3 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.